BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma

PharmAbcine Announces Positive Results for Its Novel TIE2-Activating Antibody in GLP Toxicology Study

PMC-403 can stabilize and repair damaged and pathologically leaky blood vessels, and it is being developed to treat AMD (Age-related Macular Degeneration),...

April 27, 2022 | News

Biopharmaceuticals: Faster to Market

To combat these challenges, biopharmaceuticals that are produced with the help of living organisms are playing an increasingly important role. However, the...

April 21, 2022 | Opinion

GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn

Sierra Oncology’s differentiated momelotinib has the potential to address the critical unmet medical needs of myelofibrosis patients with anaemia ...

April 14, 2022 | News

Cambrex Completes Large-Scale US API Expansion

The startup of the new manufacturing space is the culmination of a two-year project, originally announced in 2020, to increase the capacity of Cambrex's fl...

April 13, 2022 | News

Daewoong Pharmaceutical and HanAll Biopharma Invest in Turn Biotechnologies to Expand Growth Initiative

Daewoong Pharmaceutical (KRX: 069620.KS) and HanAll Biopharma (KRX: 009420.KS) today announced expansion of their open collaboration strategy by inves...

April 12, 2022 | News

CR Pharma intends to make strategic equity investment for Everest's mRNA technology platform

Partnership with CR Pharma will provide local support to navigate China regulatory pathways across mRNA vaccine platform, first in the advancemen...

April 07, 2022 | News

Singlera Genomics announces research collaboration with Astellas Pharma

Singlera Genomics Inc. today announced a research collaboration with Astellas Pharma Inc. to develop methylation-based tools to better understand biologica...

April 06, 2022 | News

CBC Group continues to expand its global healthcare ecosystem to fulfil unmet medical needs

Hasten fast-tracks transformative medicines for patients in China Hasten Biopharmaceutic Co., Ltd (China) ("Hasten") today announced that it has ...

April 01, 2022 | News

Zhimeng Biopharma Announces Dosing of First Subject in First-in-Human Phase -- Clinical Trial of CB06

The Phase I clinical trial, a randomized, double-blind and placebo-controlled study, is to evaluate the safety, pharmacokinetics and pharmacodynamics of si...

April 01, 2022 | News

Expansion of Biologics CDMO & Manufacturing Capacity Offerings at Paras Biopharmaceuticals Finland

Due to the company’s technologies, its deep scientific knowhow and the specialized skills of the Paras Biopharma team, all of Paras Biopharmaceutical...

March 29, 2022 | News

Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue Tablets to the Philippines

Daewoong Pharmaceutical (CEO Sengho Jeon & Changjae Lee) recently announced that it has submitted the New Drug Application (NDA) for a n...

March 29, 2022 | News

Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG

Furthermore, it also empowers the domestic precision immunotherapy for tumors and promotes the high-quality development of China's biopharmaceuti...

March 28, 2022 | News

Aquavit Files IND with FDA for DTX-021, a New Botulinum Toxin

DTX-021 is a botulinum toxin type A drug intended for the treatment of moderate to severe glabellar lines. DTX-021 is a highly purified and clinically test...

March 25, 2022 | News

RNAGENE Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel mRNA Therapeutics

Under the agreement, both companies will collaborate to develop next-generation mRNA-based antibody therapeutics by utilizing the proprietary mRNA platform...

March 22, 2022 | News

Stay Connected